bullish

Jyothy Laboratories - Sales in 4QFY22 Were in Line.

207 Views26 May 2022 07:54
Broker
Revenue growth is key for a company with sales of only ~INR22b. The likelihood of a consistent 15% sales growth (essential for any re-rating) continues to appear difficult
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 22-minute read)
Discussions
(Paid Plans Only)
chart-bar
Logo
Motilal Oswal
External broker reports(aggregated public sources)
Motilal Oswal Financial Services Limited
IndiaEquity Bottom-Up
Price Chart(Sign Up to Access)
analytics-chart
  • Jyothy Laboratories - Sales in 4QFY22 Were in Line.
    26 May 2022
x